The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Drug Metabolism And Disposition

• Publication date

  2011-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.111.041293PMID 21795468
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytochrome 2 C 19 * 17 Allelic Variant , Platelet Aggregation , Bleeding Events , and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement

  2011cited by this paper
• Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo‐Controlled, Crossover Comparison Studies

  2011influential reference
• An evaluation of the dilution method for identifying metabolism-dependent inhibitors (MDIs) of cytochrome P450 (CYP) enzymes

  2011cited by this paper
• Clopidogrel-drug interactions.

  2011influential reference
• Paraoxonase-1 is a major determinant of clopidogrel efficacy

  2011cited by this paper
• An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes

  2011influential reference
• No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

  2011cited by this paper
• Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement

  2010cited by this paper
• Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam.

  2010cited by this paper
• Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

  2010cited by this paper
• Review Article: Combination of Clopidogrel and Proton Pump Inhibitors: Implications for Clinicians

  2010influential reference
• System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes.

  2010cited by this paper
• Goodman and Gilman's the Pharmacological Basis of Therapeutics

  2010influential reference
• Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro

  2010cited by this paper
• ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

  2010cited by this paper
• ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

  2010cited by this paper
• An in Vitro Evaluation of the Victim and Perpetrator Potential of the Anticancer Agent Laromustine (VNP40101M), Based on Reaction Phenotyping and Inhibition and Induction of Cytochrome P450 Enzymes

  2009influential reference
• Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition.

  2009cited by this paper
• The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America

  2009influential reference
• Clopidogrel Inhibits CYP2C19‐Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms

  2009influential reference
• Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

  2009cited by this paper
• Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition.

  2009cited by this paper
• In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran

  2009cited by this paper
• Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel

  2009cited by this paper
• ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

  2008cited by this paper
• Stereoselective Disposition of Proton Pump Inhibitors

  2008cited by this paper
• Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.

  2008influential reference
• Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions

  2007influential reference
• The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy)

  2006cited by this paper
• GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

  2006influential reference
• Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.

  2006influential reference
• HIGH VOLUME BIOASSAYS TO ASSESS CYP3A4-MEDIATED DRUG INTERACTIONS: INDUCTION AND INHIBITION IN A SINGLE CELL LINE

  2005cited by this paper
• Enantiomer/Enantiomer Interactions between the S- and R- Isomers of Omeprazole in Human Cytochrome P450 Enzymes: Major Role of CYP2C19 and CYP3A4

  2005cited by this paper
• Validated assays for human cytochrome P450 activities.

  2004cited by this paper
• Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

  2004cited by this paper
• A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects

  2004influential reference
• The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.

  2003cited by this paper
• Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19

  2001influential reference
• Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.

  2000influential reference
• In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.

  2000cited by this paper
• Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices.

  2000influential reference
• Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans

  1999cited by this paper
• Lack of pharmacokinetic interaction of pantoprazole with diazepam in man.

  1996cited by this paper
• The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1A

  1994cited by this paper
• Influence of lansoprazole treatment on diazepam plasma concentrations

  1992cited by this paper
• Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole

  1990cited by this paper
• Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes

  1977cited by this paper

• Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency.

  2026cites this paper
• Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations

  2026cites this paper
• Phase 1 Study Evaluating the Effect of Food and Omeprazole-Induced Gastric pH Change on the Pharmacokinetics and Safety of Imlunestrant in Healthy Females.

  2025cites this paper
• ETRAISI registry report: clinical characteristics and related factors of outcome in reperfusion-eligible AIS patients

  2025cites this paper
• Impact of Intravenous Nitrate Treatment on Antiplatelet Effects of Clopidogrel in Acute Coronary Syndrome Patients: A Pilot Study

  2025cites this paper
• First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

  2025cites this paper
• Utilizing Physiologically Based Pharmacokinetic Models to Support Rational Medication in Chinese Elderly Population

  2025cites this paper
• Comparative effectiveness of potassium-competitive acid blockers and proton pump inhibitors in dual antiplatelet therapy patients: a nationwide cohort study

  2025cites this paper
• Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders.

  2025cites this paper
• An in vitro evaluation on metabolism of mitragynine to 9-O-demethylmitragynine.

  2024cites this paper
• Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis.

  2024cites this paper
• Impact of obesity and roux‐en‐Y gastric bypass on the pharmacokinetics of (R)‐ and (S)‐omeprazole and intragastric pH

  2024cites this paper
• Impact of fresh grape juice on the pharmacokinetics of omeprazole: results of a food–drug interaction study

  2024cites this paper
• Intestinal Drug Absorption After Subarachnoid Hemorrhage and Elective Neurosurgery: Insights From Esomeprazole Pharmacokinetics

  2024cites this paper
• Effects of treatment with clopidogrel with or without proton pump inhibitor omeprazole on the risk of ischemic stroke: a nationwide cohort study

  2024cites this paper
• A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients

  2024cites this paper
• 프로톤펌프억제제와 칼륨경쟁적 위산분비억제제의 적절한 처방

  2023cites this paper
• The impact of CYP2C19 genotype on phenoconversion by concomitant medication

  2023cites this paper
• Concomitant Use of Antiplatelet Agents and Proton-Pump Inhibitors Increases the Risk of Adverse Cardiovascular Events: A Nationwide Population-Based Cohort Study Using Balanced Operational Definitions

  2023cites this paper
• Prevalence and Safety of Prescribing PPIs with Clopidogrel in Palestine

  2023cites this paper
• Phytotoxicity Evaluation of Five Proton-Pump Inhibitors Through Plant-Based Eukaryotic Test Models

  2023cites this paper
• Pyridyl Methylsulfinyl Benzimidazole Derivatives as Promising Agents against Giardia lamblia and Trichomonas vaginalis

  2022cites this paper
• Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach

  2022cites this paper
• Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model

  2021cites this paper
• Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics

  2021cites this paper
• Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole

  2021cites this paper
• Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan

  2021influential citation
• Potential drug–drug interactions in patients with cardiovascular diseases: findings from a prospective observational study

  2021cites this paper
• Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype

  2021cites this paper
• The Association between Co-Administration of Omeprazole and Clopidogrel and Cardiovascular Outcomes

  2021cites this paper
• Preliminary in vitro approach to evaluate the drug-drug interaction potential of EST73502, a dual µ-opioid receptor partial agonist and σ1 receptor antagonist

  2021cites this paper
• Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug–Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole

  2020influential citation
• Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes

  2020cites this paper
• Chapter 25: Rheumatology/Musculoskeletal Pain: Azathioprine/TPMT, Celecoxib/CYP2C9 Case

  2020cites this paper
• Preliminary in Vitro Assessment of the Potential of EST64454, a Sigma-1 Receptor Antagonist, for Pharmacokinetic Drug-Drug Interactions.

  2020cites this paper
• Pharmacologic Treatments for Gastroesophageal and Laryngopharyngeal Reflux Disease

  2020cites this paper
• Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug–Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole

  2020cites this paper
• Effect of High‐Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long‐lasting Inhibition of CYP2C19

  2020cites this paper
• Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions.

  2019cites this paper
• Cardiovascular Outcomes Associated With Clinical Use of Citalopram and Omeprazole: A Nationwide Population‐Based Cohort Study

  2019cites this paper
• The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism

  2019cites this paper
• Different Clopidogrel Response Elicited by Lansoprazole or Esomeprazole in Patients Undergoing Neurointervention with Dual Antiplatelet Therapy

  2019cites this paper
• Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers

  2019cites this paper
• Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes)

  2019influential citation
• Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited.

  2019cites this paper
• An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides

  2018cites this paper
• Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018

  2018cites this paper
• The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo.

  2018cites this paper
• Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition

  2018cites this paper
• Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children

  2018cites this paper
• Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype

  2018cites this paper
• Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine

  2018cites this paper
• A strategy for early-risk predictions of clinical drug–drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors

  2018cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2018influential citation
• Decorporation potential of lansoprazole against radiothallium (201Tl) in internally contaminated BALB/c mice and New Zealand White rabbits

  2018cites this paper
• Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.

  2018cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2017cites this paper
• Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole.

  2017cites this paper
• Functional expression and comparative characterization of four feline P450 cytochromes using fluorescent substrates

  2017cites this paper
• Acid-Suppressive Therapy and Risk of Infections: Pros and Cons

  2017cites this paper
• Neurology of cardiopulmonary resuscitation.

  2017cites this paper
• PHARMACOKINETIC DRUG-DRUG INTERACTIONS EVALUATION OF MELOXICAM WITH SELECTED CO-PRESCRIBED DRUGS

  2017cites this paper
• Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.

  2017cites this paper
• Clinical Drug-Drug Interaction Data: Effects of Co-administered Drugs on Pharmacokinetics of Antiretroviral Agents

  2016cites this paper
• Drug–Drug Interaction of Omeprazole With the HCV Direct‐Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir

  2016cites this paper
• Proton pump inhibitors use; beware of side-effects.

  2016cites this paper
• Clinically Significant Interactions with Antidepressants

  2016cites this paper
• Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator

  2016cites this paper
• Effect of Omeprazole and Dextromethorphan on the Urinary Metabolic Ratio of Flurbiprofen.

  2016cites this paper
• The Pharmacogenetics of Cytochrome P 450 2 C 19 enzymes-Effects on Clopidogrel and Proton Pump Inhibitors

  2016cites this paper
• How Informative Are Drug‐Drug Interactions of Gene‐Drug Interactions?

  2016cites this paper
• Genotyping of CYP2C19 helps to reassure sufficient effects of antiplatelet therapy in combination with proton pump inhibitors (PPIs)

  2016cites this paper
• Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents

  2015cites this paper
• The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments

  2015cites this paper
• Clinical relevance of clopidogrel-proton pump inhibitors interaction.

  2015cites this paper
• AN IN VITRO INVESTIGATION INTO THE MECHANISM OF THE CLINICALLY RELEVANT DRUG-DRUG INTERACTION BETWEEN OMEPRAZOLE OR ESOMEPRAZOLE AND CLOPIDOGREL

  2015influential citation
• SYSTEM-DEPENDENT METABOLISM OF DRUGS BY CYTOCHROME P450: THE MECHANISTIC BASIS FOR WHY HUMAN LIVER MICROSOMES ARE SUPERIOR TO HUMAN HEPATOCYTES AT METABOLIZING MIDAZOLAM BUT INFERIOR AT METABOLIZING DESLORATADINE

  2015influential citation
• Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors

  2015cites this paper
• Effect of Proton Pump Inhibitors on the Serum Concentrations of the Selective Serotonin Reuptake Inhibitors Citalopram, Escitalopram, and Sertraline

  2015cites this paper
• DMD066597 1744..1750

  2015cites this paper
• Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway

  2015cites this paper
• Identification and mechanistic investigation of clinically important myopathic drug-drug interactions

  2014cites this paper
• Cardiovascular pharmacogenetics of anti-thrombotic agents and non-steroidal anti-inflammatory drugs.

  2014cites this paper
• pH‐Dependent Drug–Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development

  2014cites this paper
• The Stereoselectivity of CYP2C19 on R‐ and S‐isomers of Proton Pump Inhibitors

  2014cites this paper
• Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9‐mediated dose requirements of vitamin K antagonist therapy: a pilot study

  2014cites this paper
• Reversible mechanisms of enzyme inhibition and resulting clinical significance.

  2014cites this paper
• The Pharmacogenetics of Cytochrome P450 2C19 Enzymes - Effects on Clopidogrel and Proton Pump Inhibitors

  2014cites this paper
• Clopidogrel, CYP2C19 and proton pump inhibitors: What we know and what it means

  2014cites this paper
• Combination of high on-treatment platelet aggregation and low deaggregation better predicts long-term cardiovascular events in PCI patients under dual antiplatelet therapy

  2014cites this paper
• Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions

  2014cites this paper
• Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study.

  2014cites this paper
• Factors affecting carisoprodol metabolism in pain patients using urinary excretion data.

  2014cites this paper
• Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions

  2013influential citation
• Upper Gastrointestinal Symptoms and Cardiovascular Disease

  2013cites this paper
• General Considerations for Neurointerventional Procedures

  2013cites this paper
• Interacciones en el uso de antiácidos, protectores de la mucosa y antisecretores gástricos

  2013influential citation
• In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.

  2013influential citation
• Absorption of TAK-491, a new angiotensin II receptor antagonist, in animals

  2013cites this paper
• Inhibition of CYP 2 C 19 and CYP 3 A 4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions s

  2013influential citation